We observed that 11.8% of tirzepatide-treated rs1800437-CC carrier individuals experienced vomiting, compared with 9.4% for semaglutide-treated people carrying the same genotype, although the difference was not significant ( P = 0.12, two-sample z -test
doi: 10.1111/nmo.12421 14 CamilleriM.VijayvargiyaP
Moreover, continued investigation into the pleiotropic effects of GLP-1 receptor agonists may reveal other therapeutic possibilities, possibly transforming the management of many metabolic and non-metabolic disorders
To wrap things up, medications like Ozempic can be beneficial for weight management and metabolic health
Evidence based on recent studies Initially, cases of intestinal obstruction associated with GLP-1 RAs were reported by the European Medicines Agency (EMA) in 2013 [9], and this safety signal is currently being monitored by the United States (US) FDA